Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-301 in Patients with ASPH-Positive Head and Neck Cancer

GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced the dosing of the first patient in its Phase 1/2 clinical trial evaluating SNS-301 in patients with ASPH‑positive head and neck cancer who have previously received immune checkpoint inhibitors. SNS-301 is a first-in-class immunotherapy candidate utilizing a bacteriophage viral vector…

Details

Sensei Biotherapeutics to Present at Citi 14th Annual Biotech Conference

GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced that John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics, will participate in a private company panel discussion at the Citi 14th Annual Biotech Conference on Wednesday, September 4, 2019 at 3:45 p.m. ET in Boston, MA. READ MORE

Details

Sensei Biotherapeutics Announces Clinical Trial Collaboration Agreement with AstraZeneca for Two Phase 2 Studies of SNS-301

Trials to Evaluate the Safety, Tolerability and Preliminary Activity of Sensei’s SNS-301, in Combination with IMFINZI® (durvalumab), in Multiple Solid Tumor Types GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced a clinical trial collaboration with AstraZeneca to evaluate the safety, tolerability and preliminary activity of AstraZeneca’s IMFINZI® (durvalumab),…

Details

Sensei Biotherapeutics Appoints Former Head of the National Cancer Institute, Samuel Broder, M.D. to its Board of Directors

GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced the appointment of Samuel Broder, M.D. to its Board of Directors. Dr. Broder is an accomplished leader in the oncology space with more than 30 years of medical oncology and research experience. READ MORE

Details

Sensei Biotherapeutics Announces Formation of New Immuno-Oncology Advisory Board

– Company brings together world-recognized leaders in immunobiology, cancer biology, and clinical and translational medicine – GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced the formation of a new Immuno-Oncology Advisory Board (IOAB), consisting of several world-recognized and credentialed experts in the fields of immuno-oncology, tumor biology, vaccinology,…

Details

Sensei Biotherapeutics Presents First Preclinical Data on SNS-723 CAR-T and Long-Term Results on SNS-301 Data at the 2019 American Association for Cancer Research (AACR) Annual Meeting

-Multiple SNS-723 CAR constructs demonstrated significant expression of ASPH-specific CARs on T-cells, dose-dependent cell killing, and cytokine responses -Dose-dependent and durable ASPH-specific immune responses observed in patients dosed with SNS-301, consistent with earlier findings GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced new data from two programs targeting…

Details

Sensei Biotherapeutics To Present First Preclinical Data on SNS-723 and Long-Term Clinical Results on SNS-301 Data at The 2019 American Association for Cancer Research (AACR) Annual Meeting

GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced that it will present novel preclinical data on SNS-723, a first-in-class CAR-T cell therapy and additional Phase 1 data on the long-term effects of SNS-301, a first-in-class cancer immunotherapy, both targeting a novel tumor specific embryonic antigen, human aspartate β-hydroxylase…

Details

Sensei Biotherapeutics to Present at BIO CEO & Investor Conference

GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc.., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, announced today that John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics, will present a company overview at the BIO CEO & Investor Conference on Monday, February 11, 2019, at 3:45 p.m. ET in New York, NY. READ MORE

Details

Sensei Biotherapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference

GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, announced today that John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics, will present a company overview at the 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27, 2018 at 1:30 p.m. ET in New York, NY. READ MORE

Details

Sensei Biotherapeutics Presents Clinical Trial Data Demonstrating SNS-301 Induces Rapid and Robust Antigen-specific Immune Responses at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting

Dose-dependent, ASPH-specific immune responses observed Company to initiate SNS-301 Phase 2 study in multiple solid tumor indications and hematological malignancies in early 2019 GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, announced today that clinical and immunological data from the Phase 1 clinical trial of SNS-301 will be highlighted in…

Details